Mid-dose losartan mitigates diabetes-induced hepatic damage by regulating iNOS, eNOS, VEGF, and NF-κB expressions

por OLTULU, Fatih, BUHUR, Aylin, GÜREL, Çevik, KUŞÇU, Gökçe Ceren, DAĞDEVİREN, Melih, KARABAY YAVAŞOĞLU, Nefise Ülkü, KÖSE, Timur, YAVAŞOĞLU, Altuğ
Publicado 2019